Apogee Stock Soars on Positive Eczema Drug Trial Data

Key Trial Success Drives Stock Surge

Apogee Therapeutics (NASDAQ:APGE) shares surged 15% on Monday after the company announced positive 52-week data from its Phase 2 clinical trial for zumilokibart, an investigational treatment for moderate-to-severe atopic dermatitis.

Clinical Trial Highlights

The APEX trial data demonstrated that zumilokibart maintained a durable response in patients over 52 weeks with both quarterly and biannual dosing. Among patients responding at week 16, 85% maintained skin clearance (EASI-75) with a 6-month dosing schedule, and 75% did so with a 3-month schedule. The drug was reported as well tolerated.

Market Impact and Future Outlook

The positive results boost investor confidence in zumilokibart's potential as a long-acting treatment, requiring fewer annual injections than current standards. This promising outlook contributed directly to the significant stock price increase. The drug is designed as an anti-IL-13 antibody aimed at providing a more convenient treatment option.

Path to Market

Apogee anticipates releasing further 16-week induction data in the second quarter of 2026. This will support the planned initiation of Phase 3 trials in the second half of 2026, with a potential commercial launch targeted for 2029, pending regulatory approvals.

FAQ

Q: Why did Apogee Therapeutics stock increase significantly?

A: The stock rose 15% following the release of positive 52-week Phase 2 trial data for its atopic dermatitis drug, zumilokibart, which showed sustained efficacy with infrequent dosing.

Q: What is the next major milestone for zumilokibart?

A: The next key milestone is the release of Part B 16-week induction data, expected in the second quarter of 2026, which will pave the way for Phase 3 trials.

Source: Investing.com